Elagolix for Unexplained Infertility (EFFECT Trial)

"Indeed, clinicaltrials.gov attests that this medical experiment is actively recruiting participants. This study was initially published on the 15th of January 2022 and last updated on December 1st, with a quota of 100 enrollees at one center."

"Elagolix is an excellent choice for treating mild to moderate acne; it can also prove beneficial in managing polycystic ovary syndrome, premenstrual dysphoric disorder, and severe menopausal vulvovaginal atrophy."

"A total of 100 individuals with endometrioma, aged between 18 and 42, have been accepted into the trial. Admission is only possible if they meet two conditions: their Anti-Mullerian Hormone (AMH) must be greater than 0.5 and less than 10, as well as having at least one euploid embryo for transfer."

"To be included in this study, patients must fall within the 18-42 age bracket. For those younger than 18 and older than 65, there are 23 trials and 49 studies available respectively."

"Affirmative. Clinicaltrials.gov states that the research study, which was inaugurated on January 15th 2022 is currently welcoming applicants. The clinical trial necessitates 100 individuals from a single centre to partake in it."

"Given that it is a Phase 2 trial, with clinical data supporting safety but none for efficacy, Elagolix was assigned a score of two."

"At the moment, 19 trials are in effect to study Elagolix. Out of these investigations, 6 are situated at Phase 3 and have been established around Chicago, Illinois; however, there exist 608 sites conducting research on this medication across the country."